bims-midomi Biomed News
on MDM2 and mitochondria
Issue of 2026–11–01
seven papers selected by
Gavin McStay, Liverpool John Moores University



  1. Biochemistry (Mosc). 2026 Oct;91(10): 1937-1950
      Emergence of drug resistance remains a major challenge in oncology and is closely associated with tumor progression. Activation of the tumor-suppressive activity of p53 through selective inhibition of its negative regulator MDM2 is a promising strategy for anticancer therapy. MDM2 antagonists, which have been extensively evaluated in clinical trials over the past two decades, could lose efficacy because tumor cells acquire resistance to these agents. We found that SH-SY5Y neuroblastoma cells resistant to the MDM2 antagonist RG7388 were less sensitive to ferroptosis induction and showed alterations in cell cycle distribution. In addition, both parental and resistant cells were highly sensitive to autophagy induction. Finally, combining RG7388 with various inhibitors of cellular metabolism and other anticancer compounds increased its cytotoxicity and could facilitate partial or complete overcoming of this type of resistance.
    Keywords:  MDM2; RG7388; chemotherapy; drug resistance; p53; tumor cells
    DOI:  https://doi.org/10.1134/S0006297926601875
  2. PLoS One. 2026 ;21(10): e0361362
    PLOS One Editors
      [This corrects the article DOI: 10.1371/journal.pone.0343551.].
    DOI:  https://doi.org/10.1371/journal.pone.0361362
  3. Cell Death Dis. 2026 Aug 01. pii: 920. [Epub ahead of print]17(1):
      MDM2 is an oncogenic E3 ubiquitin ligase best known for targeting the tumor suppressor p53 and is frequently amplified in human cancers, including dedifferentiated liposarcoma (DDLPS). We show that supraphysiological MDM2 expression can be exploited to reprogram its ligase activity toward selective degradation of oncogenic transcriptional machinery. Using a substrate substitution strategy, we developed an MDM2-recruiting degrader dCDK9-010 that targets positive transcription elongation factor b, inducing its proteasomal degradation while simultaneously stabilizing p53. This dual action disrupts RNA polymerase II abundance and elongation, preferentially impairing enhancer-driven transcriptional programs that sustain tumor growth. In DDLPS models, this approach produces potent antitumor activity with favorable pharmacokinetic and safety profiles, triggers apoptosis, and enhances macrophage-mediated tumor cell clearance. These findings establish substrate substitution-based reprogramming of MDM2 as a generalizable targeted protein degradation strategy and identify MDM2 amplification as a predictive biomarker for therapeutic response across cancer types, with particular relevance to liposarcoma.
    DOI:  https://doi.org/10.1038/s41419-026-09134-w
  4. J Mol Graph Model. 2026 Oct 23. pii: S1093-3263(26)00354-2. [Epub ahead of print]150 109628
      MDM2 is a principal negative regulator of the p53 tumor suppressor pathway, and pharmacological disruption of the p53-MDM2 interaction remains an important strategy for anticancer drug discovery. In this study, 176,407 drug-like compounds from the Otava Drug-Like Green Collection were evaluated through a multi-stage structure-based virtual screening workflow targeting the p53-binding pocket of MDM2. LigPrep preparation generated 256,757 ligand structures by enumerating possible protonation, tautomeric, stereochemical, and conformational states. Initial Glide/SP screening of these prepared states was followed by retention of the most favorable-scoring state for each Otava parent compound; the resulting Top 100 unique parent compounds were subsequently evaluated by Glide/XP, induced-fit docking, and quantum-polarized ligand docking. Cancer-QSAR scoring retained 32 candidates with predicted anticancer activity scores ≥ 0.50, after which their ADME and toxicity profiles were characterized for comparative assessment. From this 32-compound pool, five candidates (D1-D5) were advanced to 1 μs molecular dynamics simulations together with apo MDM2 and the positive control AMG232. Dynamic analyses showed that D5 maintained a stable binding-pocket position comparable to AMG232, whereas D3 exhibited substantially greater positional displacement despite showing the most favorable relative MM/GBSA binding-energy estimate among the candidate ligands; its trajectory-level binding geometry remained unresolved. Post-MD MM/GBSA calculations yielded the most favorable relative binding-energy estimate for D3, followed by D5, with average MM/GBSA estimates of -102.66 and -88.44 kcal/mol, respectively. Scaffold enrichment analysis further revealed marked overrepresentation of indole-containing and indole-coumarin-containing chemotypes among the final hits. Structural novelty analysis further indicated that D1-D32 did not show exact, parent-level, or Bemis-Murcko scaffold matches to the previous in-house/patented MDM2 comparator set. Collectively, these findings identify D3 and D5 as computationally prioritized virtual-screening candidates that warrant further biochemical and cellular validation.
    Keywords:  ADMET profiling; MDM2; MM/GBSA; Molecular dynamics simulation; Structure-based virtual screening; p53–MDM2 interaction
    DOI:  https://doi.org/10.1016/j.jmgm.2026.109628
  5. Front Immunol. 2026 ;17 1910235
      Adoptive T-cell therapies using chimeric antigen receptors (CARs) or engineered T-cell receptors (TCRs) have transformed cancer treatment but remain limited by poor persistence and progressive T-cell exhaustion. Manufacturing strategies that promote memory T-cell formation may improve therapeutic durability. Here we investigated whether transient pharmacologic activation of the p53 pathway influences the differentiation and function of human CD8+ T cells. p53 expression was minimal in quiescent naïve CD8+ T cells but was rapidly induced following T-cell receptor activation. Pharmacologic inhibition of the p53 negative regulator MDM2 increased p53 protein levels and promoted expansion of central memory and stem-like memory T-cell subsets during clonal proliferation. Treated cells displayed enhanced mitochondrial fitness, increased polyfunctional cytokine production, and transcriptional programs consistent with memory differentiation and reduced exhaustion. Importantly, TCR-engineered CD8+ T cells generated in the presence of the MDM2 inhibitor Navtemadlin demonstrated superior tumor-cell killing in vitro compared with conventionally manufactured cells. These findings identify transient p53 activation as a pharmacologic strategy to enhance memory programming during T-cell manufacturing and suggest a clinically feasible approach to improve the efficacy of adoptive T-cell immunotherapies.
    Keywords:  CD8; T-cell memory; exhaustion; immunotherapy; metabolic fitness; p53
    DOI:  https://doi.org/10.3389/fimmu.2026.1910235
  6. J Zhejiang Univ Sci B. 2026 Aug 23. pii: 1673-1581(2026)10-1140-13. [Epub ahead of print]27(10): 1140-1152
      Murine double minute 2 (MDM2) and murine double minute 4 (MDMX) are critical for the regulation of tumor protein 53 (p53) function and apoptosis. This study compares the Mdm2/x gene sequences and functional variations of subterranean zokors from the High Plateau and the Loess Plateau. The findings reveal the molecular mechanisms by which Mdm2/x variations drive adaptation to extremely high-altitude conditions-including low oxygen, cold temperatures, and perpetual darkness in underground environments. We cloned and analyzed Mdm2/x sequences from two distinct ecological groups of subterranean rodents, Myospalax baileyi (plateau zokor) and Myospalax cansus (Gansu zokor), and reconstructed phylogenetic trees for a series of subterranean rodents and mammals, as well as the aboveground laboratory rat and humans. We found that MDM2/X in M. baileyi and M. cansus are involved in the p53-dependent low apoptosis rate, and the variations of phosphorylation sites at the C-terminus of MDM2 contribute to upregulation of p53 transcription and protein expression. We propose that gene evolutionary mechanisms enable survival under these severe combined pressures, and believe that our findings provide critical insight into how genetic modifications drive physiological resilience in Earth's most challenging ecosystems.
    Keywords:  Adaptation; Apoptosis; Extreme environment; Murine double minute 2/4 (MDM2/X); Plateau zokor
    DOI:  https://doi.org/10.1631/jzus.B2500281